K Ng

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Vitamin D for Prevention and Treatment of Colorectal Cancer: What is the Evidence?
    Kimmie Ng
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215
    Curr Colorectal Cancer Rep 10:339-345. 2014
  2. pmc Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana 1220, Boston, MA 02215, USA
    Clin Cancer Res 19:3987-95. 2013
  3. pmc Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
    K Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 101:916-23. 2009
  4. pmc Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies
    Y Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Br J Cancer 102:1422-7. 2010

Detail Information

Publications4

  1. pmc Vitamin D for Prevention and Treatment of Colorectal Cancer: What is the Evidence?
    Kimmie Ng
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215
    Curr Colorectal Cancer Rep 10:339-345. 2014
    ..In this review, the available published evidence on vitamin D's activity in CRC will be summarized, spanning preclinical, epidemiological, and clinical studies, and future research directions will be discussed...
  2. pmc Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana 1220, Boston, MA 02215, USA
    Clin Cancer Res 19:3987-95. 2013
    ..Everolimus, an oral inhibitor of mTOR, showed efficacy in patients with metastatic colorectal cancers in phase I studies...
  3. pmc Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
    K Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 101:916-23. 2009
    ....
  4. pmc Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies
    Y Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Br J Cancer 102:1422-7. 2010
    ..Studies evaluating vitamin D status in relation to pancreatic cancer risk have yielded inconsistent results...